Table 3.

Univariate Analysis of Risk Factors for Readmissions

Risk Factor	Odds Ratio* (95% CI)	P Value
Age (per 10-year increments)	1.01 (.97-1.05)	.54
Gender	.97 (.41-2.30)	.95
Diagnosis (acute leukemia/MDS versus others)	.84 (.34-2.06)	.70
Disease risk
Low	-	-
Intermediate	.35 (.09-1.41)	.08
High	1.26 (.50-3.16)	.12
Disease status (chemosensitive versus refractory)	.70 (.28-1.75)	.45
Prior number of therapy	1.01 (.67-1.52)	.95
Prior radiation therapy	.36 (.07-1.82)	.22
Prior autologous transplantation	.51 (.10-2.66)	.42
KPS	.98 (.93-1.03)	.37
HCT-CI	1.22 (.97-1.53)	.10
High busulfan dose (high versus low)	2.18 (.84-5.67)	.11
GVHD prophylaxis (MMF versus MTX)	.85 (.36-2.02)	.71
Pretransplantation ATG	1.55 (.65-3.71)	.33
Donor type (sibling versus unrelated)	.84 (.36-1.96)	.69
HLA mismatch	3.0 (.08-107.45)	.55
Infused CD34 cell dose	.97 (.85-1.12)	.69
Infused CD3 cell dose	.98 (.95-1.02)	.30
Days to neutrophil recovery	.95 (.84-1.08)	.41
Days to platelet recovery	1.11 (.97-1.26)	.13
Acute GVHD, median days to onset (range)	1.00 (.99-1.02)	.81
Severity of acute GVHD (< grade II versus ≥ grade II)	1.68 (.65-4.38)	.29
Length of stay for index admission	.99 (.93-1.05)	.78
Infection during index admission	2.72 (1.06-7.01)	.04
Caregiver (spouse versus other)	.49 (.21-1.15)	.10
Number of caregivers (1 versus > 1)	1.15 (.35-3.76)	.82

CI indicates confidence interval; MDS, myelodysplastic syndrome; KPS, Karnofsky performance status; ATG, antithymocyte globulin; HCT-CI, hematopoietic cell transplantation–comorbidity index; MMF, mycophenolate mofetil; MTX, methotrexate; HLA, human leukocyte antigen; GVHD, graft-versus-host disease.

^*Odds ratio of greater than 1 implies risk factor more in the readmission group compared to nonreadmission group.